The Discriminative Effects of Tramadol in Humans

• Status: Completed
• Trial end date: 2011-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This research is part of a set of studies whose purpose is to test whether tramadol can be used for the treatment of opioid addiction. Tramadol is already available in the United States as a pain medicine marketed as Ultram. It has effects similar to morphine, and it may also have effects similar to other drugs like stimulants. The doses of tramadol used in this study are higher than those generally used for the treatment of pain. To be in this study a participant must be a user of opioids (drugs like heroin) and stimulants (drugs like cocaine), but cannot be addicted to either. The person must be between 21-55 years old, and generally healthy. Up to 12 people will take part in this study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute on Drug Abuse (NIDA)
• Treatments: Hydromorphone; Methylphenidate; Tramadol

Criteria

Inclusion Criteria:

• Study subjects are male and female non-dependent opioid users with active stimulant use.

• Between the ages of 21-55

• In good physical health

• Without significant psychiatric illness besides their drug use.

• Females are required to provide a negative pregnancy test prior to study participation.

Exclusion Criteria:

• Subjects are excluded if they have evidence of significant medical (e.g., insulin dependent diabetes mellitus) or psychiatric (e.g., schizophrenia) illness.

• Subjects with a history of seizures will be excluded.

• Persons with current history of significant alcohol or sedative/hypnotic drug use will be excluded from study participation.

• Applicants seeking treatment for their substance abuse will not be admitted to the study, and will be provided information about treatment services available.